Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
The rally attracted around 250 riders, including professionals and amateurs.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
A research group led by Ben-Gurion University of the Negev managed to produce an innovative microchip for creating sperm in a culture by using a microfluidic system.
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Subscribe To Our Newsletter & Stay Updated
